Ranitidine Bismuth Citrate
Basic information
- CAS
128345-62-0- Standard SMILES
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3]- InChIKey
XAUTYMZTJWXZHZ-UHFFFAOYSA-K- Molecular formula
- C19H27BiN4O10S
- Average molar mass
- 712.5 g/mol
- Monoisotopic mass
- 712.12519
Overview
Ranitidine Bismuth Citrate is a member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.
Names & identifiers
- Preferred name
- Ranitidine Bismuth Citrate
- IUPAC
- bismuth;1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate
- English name
- Ranitidinebismuthcitrate
- Molecular formula
- C19H30N4O10S
- Molecular weight
- 506.53
Names & synonyms
TritecRanitidine bismuth citrate128345-62-0GR 122311XGR-122311X7AJ51I17KGDTXSID801027716N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, compound with bismuth(3(+)) citrate (1:1)AzanplusGR122311XRefChem:55967DTXCID101513293
Show more names
PyloridGastrimutoRanitidine bismutrexRANTIDINEBISMUTHCITRATETIANFU CHEM-- Ranitidinebismuthcitrate2-Hydroxy-1,2,3-propanetricarboxylic acid bismuth(3+) salt compd with N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine
AzamplusElicodilHeliradPylorisanUNII-7AJ51I17KGRANITIDINEBISMUTHCITRATERANITIDINE BISMUTH CITRATE [USAN]Ranitidine bismuth citrate [USAN:BAN]
Database identifiers
- CAS
128345-62-0- PubChem CID
- 62984
- DTXSID
DTXSID801027716- ChEMBL
CHEMBL2111286- UNII
- 7AJ51I17KG
Properties
Computed structural properties
- Topological polar surface area
- 252 Ų
- Hydrogen bond donors
- 3
- Hydrogen bond acceptors
- 14
- Rotatable bonds
- 11
- Heavy atoms
- 35
- Formal charge
- 0
- Complexity
- 558
Experimental & physicochemical properties
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physicochemical properties
- InChIKey
- DLLAJOLFPOWVLQ-UHFFFAOYSA-N
- SMILES
- C(O)(C(=O)O)(CC(=O)O)CC(=O)O.C(C1=CC=C(CSCCNC(NC)=CN(=O)=O)O1)N(C)C
- FDA UNII
- 7 AJ51I17KG · 7AJ51I17KG
Chemistry & industry
Pharmacology
ATC Code
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
MeSH Pharmacological Classification
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.
Applications
DescriptionRanitidine bismuth citrate, a novel salt formed from ranitidine and a bismuth citrate complex, is a new agent introduced in the United Kingdom for the treatment of duodenal and benign gastric ulcers, for eradication of Helicobacfer pylori, and for prevention of relapse of duodenal ulcer when administered in combination with an antibiotic such as clarithromycin or amoxicillin. Ranitidine is a potent histamine H2-receptor antagonist with ability to inhibit gastric acid secretion. Other type of agents such as tripotassium dicitrato bismuthate exert their therapeutic effects in peptic ulceration by providing a protective coating to the ulcer crater, stimulating endogenous prostaglandin production, and inhibiting pepsin activity. More significantly, they inhibit micro-organism Helicobacfer pylori, a prevalent, specifically human pathogen associated with gastritis and gastric ulcers. The title compound possesses a novel combination of properties of the above two types of drugs and displays excellent therapeutic efficacy in clinical studies. Ranitidine bismuth citrate is being investigated for use in gastritis and non-ulcerating dyspepsia, acute healing of gastrointestinal ulcer and in prevention of the recurrence of peptic ulcer disease.
UsesAntagonist (to histamine H2receptors).
Preparation methods
Preparation① A solution containing Ranitidinebismuthcitrate is obtained by reacting ranitrate with ranitrate at 90–95°C; ② The solution containing Ranitidinebismuthcitrate obtained in step ① is cooled to 50–60°C, activated carbon is added, and the solution is kept at this temperature for decolorization for 20–30 minutes; ③ The solution is filtered, the filtrate is added to self-made anhydrous ethanol and stirred to crystallize, then filtered again. The filter cake is dried to obtain Ranitidinebismuthcitrate.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…